22 results
6-K
EX-99.1
IPHA
Innate Pharma
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
to the maturity of clinical trials and the non-inclusion, as a precautionary measure, of subcontracting expenses with a supplier whose agreement is in the process
6-K
EX-99.2
IPHA
Innate Pharma
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
to the maturity of clinical trials and the non-inclusion, as a precautionary measure, of subcontracting expenses with a supplier whose agreement … of the construction in order to pay the supplier payments as they become due. As of December 31, 2018 and 2019, the loan was raised at an amount of €1,300 thousand
6-K
EX-99.1
IPHA
Innate Pharma
14 Sep 23
Innate Pharma S.a. 6-K
6:00am
, of subcontracting expenses with a supplier whose agreement is in the process of being renewed as of June 30, 2023. In addition, this decrease is also explained
6-K
EX-99.2
7vammu3
15 Sep 22
Innate Pharma Reports First Half 2022 Financial Results and Business Update
6:12am
6-K
EX-99.2
d4tfpimi87j3y 1q
15 Sep 21
Innate Pharma Reports First Half 2021 Financial Results and Business Update
6:07am
20-F
2rgxqpfg6g25j
24 Apr 20
Annual report (foreign)
10:43am
424B4
6y42x0
18 Oct 19
Prospectus supplement with pricing info
4:08pm
F-1/A
bqwuvi34 5z2k
4 Oct 19
Registration statement (foreign) (amended)
4:56pm
F-1
EX-10.2
7ey897tdty0atrtyyuh
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
d2hqrfkocb vb16
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.3
xwpjy xzj
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.4
3kfxcc
20 Sep 19
Registration statement (foreign)
4:08pm
DRS/A
EX-10.3
jij932kuugl6p0a08p
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
2hpcb3rq7wox3qx9cle
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
EX-10.4
uvejcqa5221zu
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
EX-10.2
d9139sqkhz
30 Aug 19
Draft registration statement (amended)
12:00am